During the past five years, management strategies for resectable lung cancer have advanced significantly. Once treated almost exclusively with upfront surgery, stage II and stage III of this disease are now increasingly approached with neoadjuvant immunotherapy. An approach that aims not only to prevent cancer from spreading, but also to achieve a more durable, long-term response.
Patrick Forde, MB, BCh, PhD, Prendergast Professor of Immuno-Oncology at Trinity College Dublin and Consultant Medical Oncologist at St. James Hospital Dublin, will address the continued integration of this treatment option during his opening keynote Redefining Early-Stage NSCLC: Lessons from Neoadjuvant Immunotherapy Trials at the IASLC | ASCO North America Conference on Lung Cancer (NACLC) in Chicago.
Join us at the #NACLC25!
Don’t miss Dr. Patrick Forde’s opening keynote and the latest insights from experts in lung cancer research. Register by December 7 to receive all in-person and online access. Register Here
“During my lecture at NACLC, I will review how neoadjuvant immunotherapy became a mainstay of the management of resectable lung cancer with the potential for long-term survival benefits after short courses of treatment,” Dr. Forde said. “I will also explore the ongoing studies and research questions that are emerging in this very dynamic area of cancer research.”
Dr. Forde’s keynote address will open the conference with an expert look at the evolving role of neoadjuvant immunotherapy in lung cancer care and the ongoing need to refine its uses to maximize patient outcomes. The presentation will take place at 1:00 PM CST on Friday, December 5, during the conference’s opening ceremony. The session will be chaired by Ramesh Rengan, MD, PhD, and Kristen Marrone, MD.
“Our early clinical trial looked at single-agent immunotherapy prior to surgery for lung cancer, even before it was approved for advanced lung cancer,” Dr. Forde said. “Serendipitously, we found that many of the patients’ cancers regressed quickly, and some did not have any residual cancer at the time of surgery. That finding led us to continue to study neoadjuvant therapy during the past decade, leading to many advances in this area of research.”
NACLC is a must-attend event for many in the lung cancer community, including Dr. Forde, who shared his excitement for the conference.
“I am really looking forward to catching up with colleagues across specialties involved in lung cancer management as well as with patient advocates who will be at the meeting, all focused on detecting and curing lung cancer,” he said.
